HESCHl H. ROTMENSCH, M.D.; BERNARD BELHASSEN, M.D.; BRIAN N. SWANSON, Ph.D.; DAVID SHOSHANI, M.D.; SCOTT R. SPIELMAN, M.D.; ARNOLD J. GREENSPON, M.D.; ALLAN M. GREENSPAN, M.D.; PETER H. VLASSES, Pharm.D.; LEONARD N. HOROWITZ, M.D.
ROTMENSCH HH, BELHASSEN B, SWANSON BN, SHOSHANI D, SPIELMAN SR, GREENSPON AJ, et al. Steady-State Serum Amiodarone Concentrations: Relationships with Antiarrhythmic Efficacy and Toxicity. Ann Intern Med. 1984;101:462-469. doi: 10.7326/0003-4819-101-4-462
Download citation file:
Published: Ann Intern Med. 1984;101(4):462-469.
The relationship of apparent steady-state serum concentrations of amiodarone and its metabolite, desethylamiodarone, to therapeutic and toxic effects was assessed in 127 patients who had treatment-resistant ventricular or supraventricular arrhythmias or were intolerant to other agents. After at least 2 months (mean, 9.8) of treatment with daily maintenance doses of 200 to 600 mg, arrhythmias were effectively suppressed in 78% of patients. Arrhythmias recurred in 47% of patients with serum amiodarone concentrations of less than 1.0 mg/L, whereas only 14% of patients with higher concentrations had recurrences (p < 0.005). Side effects, most of them mild, occurred in 57%; only 9 patients required discontinuation of drug therapy. The risk of developing adverse reactions was related to serum amiodarone concentrations (p < 0.0001). Adverse reactions were common in patients with serum values exceeding 2.5 mg/L, although pulmonary complications did occur at lower concentrations. Monitoring serum amiodarone concentrations may differentiate failure of drug therapy from suboptimal dosing and reduce the incidence of concentration-related side effects.
Learn more about subscription options.
Register Now for a free account.
Cardiology, Rhythm Disorders and Devices.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only